Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 781 AL 795

The Placebo Response in Double-Blind Randomised Trials Evaluating Regenerative Therapies for Parkinson's Disease: A Systematic Review and Meta-Analysis

Polgar S, Buultjens M, Wijeratne T, Finkelstein DI, Mohamed S, Karimi L.

J Parkinsons Dis. 2022;12(3):759-771. doi: 10.3233/JPD-212610.

A complex form of hereditary spastic paraplegia harboring a novel variant, p.W1515*, in the SPG11 gene

Daida K, Nishioka Y, Li Y, Yoshino H, Funayama M, Hattori N, Nishioka K.

eNeurologicalSci. 2022 Jan 3;26:100391. doi: 10.1016/j.ensci.2021.100391. eCollection 2022 Mar.

A brain network for deep brain stimulation induced cognitive decline in Parkinson's disease

Reich MM, Hsu J, Ferguson M, Schaper FLWVJ, Joutsa J, Roothans J, Nickl RC, Frankemolle-Gilbert A, Alberts J, Volkmann J, Fox MD.

Brain. 2022 May 24;145(4):1410-1421. doi: 10.1093/brain/awac012.

Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases

Agrawal I, Tripathi P, Biswas S.

Drug Metab Rev. 2022 Feb;54(1):22-36. doi: 10.1080/03602532.2022.2029475. Epub 2022 Jan 24.

Progranulin as a therapeutic target in neurodegenerative diseases

Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A.

Trends Pharmacol Sci. 2022 Aug;43(8):641-652. doi: 10.1016/j.tips.2021.11.015. Epub 2022 Jan 15.

Heterogeneous digital biomarker integration out-performs patient self-reports in predicting Parkinson's disease

Deng K, Li Y, Zhang H, Wang J, Albin RL, Guan Y.

Commun Biol. 2022 Jan 17;5(1):58. doi: 10.1038/s42003-022-03002-x.

Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models

Zhang J, Sun B, Yang J, Chen Z, Li Z, Zhang N, Li H, Shen L.

Mol Med Rep. 2022 Mar;25(3):91. doi: 10.3892/mmr.2022.12607. Epub 2022 Jan 18.

Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment

Hansen CA, Miller DR, Annarumma S, Rusch CT, Ramirez-Zamora A, Khoshbouei H.

J Neurol. 2022 Jun;269(6):2892-2909. doi: 10.1007/s00415-022-10963-w. Epub 2022 Jan 17.

Drosophila: A Model to Study the Pathogenesis of Parkinson's Disease

Rahul, Siddique YH.

CNS Neurol Disord Drug Targets. 2022;21(3):259-277. doi: 10.2174/1871527320666210809120621.

Natural Products as Sources of Multitarget Compounds: Advances in the Development of Ferulic Acid as Multitarget Therapeutic

Kaur R, Sood A, Lang DK, Arora R, Kumar N, Diwan V, Saini B.

Curr Top Med Chem. 2022 Mar 4;22(5):347-365. doi: 10.2174/1568026622666220117105740.

mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis

Palma JA, Martinez J, Millar Vernetti P, Ma T, Perez MA, Zhong J, Qian Y, Dutta S, Maina KN, Siddique I, Bitan G, Ades-Aron B, Shepherd TM, Kang UJ, Kaufmann H.

Mov Disord. 2022 Apr;37(4):778-789. doi: 10.1002/mds.28923. Epub 2022 Jan 18.

Infectious Agents as Potential Drivers of α-Synucleinopathies

Linard M, Ravier A, Mougué L, Grgurina I, Boutillier AL, Foubert-Samier A, Blanc F, Helmer C.

Mov Disord. 2022 Mar;37(3):464-477. doi: 10.1002/mds.28925. Epub 2022 Jan 18.

Subthalamic deep brain stimulation in Parkinson's disease with SNCA mutations: Based on the follow-up to 10 years

Youn J, Oyama G, Hattori N, Shimo Y, Kuusimäki T, Kaasinen V, Antonini A, Kim D, Lee JI, Cho KR, Cho JW.

Brain Behav. 2022 Feb;12(2):e2503. doi: 10.1002/brb3.2503. Epub 2022 Jan 18.

Redesigning therapies for pantothenate kinase-associated neurodegeneration

Munshi MI, Yao SJ, Ben Mamoun C.

J Biol Chem. 2022 Mar;298(3):101577. doi: 10.1016/j.jbc.2022.101577. Epub 2022 Jan 15.

Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways

Eldeeb MA, Ragheb MA, Soliman MH, Fahlman RP.

Neurotox Res. 2022 Feb;40(1):298-318. doi: 10.1007/s12640-021-00396-0. Epub 2022 Jan 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias